MedTrace Logo

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

NCT04904120 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2023-11-07

No results posted yet for this study

Summary

The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.

Conditions

  • Melanoma (Skin)
  • Melanoma Stage IV
  • Melanoma, Uveal
  • Melanoma, Mucosal

Interventions

DRUG

[203Pb]VMT01

Diagnostic imaging radiopharmaceutical; by intravenous infusion

DRUG

[68Ga]VMT02

Diagnostic imaging radiopharmaceutical; by intravenous infusion

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Perspective Therapeutics

    lead INDUSTRY

Principal Investigators

  • Frances L Johnson, MD · Perspective Therapeutics

  • Geoffrey B Johnson, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2022-09-20
Completion
2022-09-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04904120 on ClinicalTrials.gov